On 4 February 2026, Mexican-headquartered Saya Biologics announced that it has entered a strategic collaboration agreement with Kashiv BioSciences for commercialisation of an undisclosed supportive biosimilar oncology therapy in Mexico and the Central America and Caribbean (CAC) region, covering 11 countries.
Under the agreement, Kashiv BioSciences will manufacture and supply the biosimilar to Saya Biologics, whilst Saya Biologics will be responsible for regulatory registration, commercialisation, and distribution across the region. According to the announcement, Saya has already submitted a regulatory dossier for the biosimilar to local authorities.
Kashiv has recently entered into a number of commercialisation agreements in relation to its omalizumab biosimilar, ADL-018. On 11 August 2025, Kashiv announced that it entered into a licence and supply agreement with Brazilian pharmaceutical company, CRISTÁLIA, for ADL-018, for the Latin American Market. Kashiv had previously entered into agreements for commercialisation of ADL-018 in other regions, including with MS Pharma for MENA markets (August 2025) and Alvotech for the EU, UK, Australia, Canada and New Zealand (AVT23, October 2023). A marketing application for AVT23 was accepted by the UK’s MHRA in March 2025.